Fassel H, McGuinn C. Haemophilia: factoring in new therapies. Br J Haematol. 2021;194(5):835–50.

Article  Google Scholar 

BioMarin Pharmaceutical Inc. First gene therapy for adults with severe hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), approved by European Commission (EC) [media release]. 24 Aug 2022. https://investors.biomarin.com/.

BioMarin Pharmaceutical Inc. BioMarin receives European orphan drug designation for BMN 270, first investigational AAV-factor VIII gene therapy for patients with hemophilia A [media release]. 24 Mar 2016. https://www.biomarin.com/.

BioMarin Pharmaceutical Inc. BioMarin receives orphan drug designation from FDA for first AAV-factor VIII gene therapy, BMN 270, for patients with hemophilia A [media release]. 1 Mar 2016. https://www.biomarin.com/.

BioMarin Pharmaceutical Inc. BioMarin receives access to priority medicines (PRIME) regulatory support from EMA for BMN 270 gene therapy in hemophilia A [media release]. 1 Feb 2017. https://www.biomarin.com/.

BioMarin Pharmaceutical Inc. FDA grants breakthrough therapy designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A [media release]. 26 Oct 2017. https://www.biomarin.com/.

BioMarin Pharmaceutical Inc. BioMarin announces FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted to valoctocogene roxaparvovec, investigational gene therapy for hemophilia A [media release]. 8 Mar 2021. https://www.biomarin.com/.

BioMarin International Ltd. Valoctocogene roxaparvovec (ROCTAVIAN™): EU summary of product characteristics. 2022. https://ec.europa.eu/health/documents/community-register/2022/20220824156641/anx_156641_en.pdf. Accessed 12 Sep 2022.

BioMarin Pharmaceutical Inc. BioMarin licenses factor VIII gene therapy program for hemophilia A from University College London and St. Jude Children's Research Hospital [media release]. 21 Feb 2013. https://www.biomarin.com/.

Bunting S, Zhang L, Xie L, et al. Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice. Mol Ther. 2018;26(2):496–509.

CAS  Article  Google Scholar 

Sihn CR, Handyside B, Liu S, et al. Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers. Mol Ther Methods Clin Dev. 2022;24:142–53.

CAS  Article  Google Scholar 

Long BR, Sandza K, Holcomb J, et al. The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy. Mol Ther Methods Clin Dev. 2019;13:440–52.

CAS  Article  Google Scholar 

Fonck C, Su C, Arens J, et al. Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy. Gene Ther. 2022. https://doi.org/10.1038/s41434-022-00318-5.

Article  PubMed  Google Scholar 

Zhang L, Handyside B, Murphy R, et al. Prednisolone does not regulate factor VIII expression in mice receiving AAV5-hFVIII-SQ: valoctocogene roxaparvovec. Mol Ther Methods Clin Dev. 2020;17:13–20.

CAS  Article  Google Scholar 

Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–25.

CAS  Article  Google Scholar 

Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519–30.

CAS  Article  Google Scholar 

Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med. 2020;382(1):29–40.

CAS  Article  Google Scholar 

Pasi KJ, Laffan M, Rangarajan S, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia. 2021;27(6):947–56.

CAS  Article  Google Scholar 

Long BR, Veron P, Kuranda K, et al. Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A. Mol Ther. 2021;29(2):597–610.

CAS  Article  Google Scholar 

BioMarin Pharmaceutical Inc. FDA files ARUP Laboratories' AAV5 CDx for hemophilia A gene therapy treatment [media release]. 20 Feb 2020. https://www.biomarin.com/.